Kameda Medical Center, a leading Japanese institute, published Ibex Prosate and Ibex Breast validation study results in the peer-reviewed journal Pathology, demonstrating excellent outcomes in detecting cancer and other pathologies in prostate and breast biopsies among a Japanese cohort. Prof. Junya Fukuoka, MD, PhD, Chair of the Department of Pathology at Kameda Medical Center, Chair of the Department of Pathology Informatics at Nagasaki University, was the study’s primary investigator.
The study evaluated the performance of Ibex’s digital pathology AI platform in detecting a broad range of pathologies in 100 breast and 100 prostate biopsies taken from a Japanese patient cohort. Ibex’s platform demonstrated excellent outcomes, showcasing its ability to accurately detect both cancerous and non-cancerous features. During the study, Ibex Prostate demonstrated high accuracy in detecting prostate adenocarcinoma with an Area Under the Curve (AUC) of 0.988. The AI algorithm was also highly accurate in cancer grading, specifically differentiating between low and medium/high-grade Gleason scores with an AUC of 0.994, as well as in identifying perineural invasion. In several cases, Ibex Prostate’s AI algorithm accurately identified higher Gleason scores than previously evaluated by a pathologist and unveiled previously undetected cancer, showcasing its potential to enhance diagnostic accuracy and reduce inter-observer variability. Similarly, Ibex Breast showed high accuracy in detecting invasive breast cancer (AUC of 0.997) and in detecting ductal carcinoma in situ (DCIS) (AUC of 0.996), as well as in identifying other important pathologies, such as lymphovascular invasion.
The current Ibex offering was formerly known as Galen. Please note that any mention of Galen within these materials refers to a product now known as Ibex.
